Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Next Previous
Trial Profile

A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan (Primary) ; Enalapril
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms PERI-STEMI

Most Recent Events

  • 20 Oct 2021 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027, as per Trial design published in the Clinical Cardiology
  • 20 Oct 2021 Trial design, published in the Clinical Cardiology
  • 23 Sep 2021 Doses for active comparator Enalapril have been changed from 1.25 mg, 2.5 mg and 5 mg to 2.5 mg, 5 mg and 10 mg respectively.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top